FR104
Based on 2 publication(s) in Google Scholar
FR104 is a selective CD28 inhibitor (binding to CD28 with a Kd value of 4.6 nM; ED50 value of 7.5 ng/mL). FR104 blocks the binding of CD28 to CD80/CD86 and ICOSL, inhibiting conventional T cell costimulation, proliferation, IL-2 secretion, alloantigen responses, and donor-specific alloantibody production. FR104 does not affect the CTLA-4/PD-L1 pathway, preserves the suppressive function of regulatory T cells, and accumulates Helios-negative Foxp3-positive regulatory T cells. FR104 has a prolonged half-life via pegylation (PEG300) (HY-Y0873) and sustained receptor occupancy, and alleviates central nervous system inflammation, demyelinating lesions, and anti-rhMOG responses. FR104 can be used for research on graft-versus-host disease, renal allograft rejection, and experimental autoimmune encephalomyelitis.
For research use only. We do not sell to patients.
- Purity : 97.26%
- Molecular Weight:145.08 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) FR104
More
Biological Activity
Description
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
IL-2 0.027 μg/mL (IC50) |
CD28 4.6 nM (Kd) |
CD28 0.32 μg/mL (ED50) |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| PBMC | IC50 |
0.16 μg/mL
|
Inhibition of allogeneic T cell proliferation in human PBMC mixed lymphocyte reaction assessed by 3H-thymidine incorporation after 5 days.
Inhibition of allogeneic T cell proliferation in human PBMC mixed lymphocyte reaction assessed by 3H-thymidine incorporation after 5 days.
|
22759318 |
| Jurkat | IC50 |
0.027 μg/mL
|
Inhibition of IL-2 secretion by superantigen-stimulated Jurkat T cells co-cultured with Raji B cells assessed by ELISA after 48 hrs.
Inhibition of IL-2 secretion by superantigen-stimulated Jurkat T cells co-cultured with Raji B cells assessed by ELISA after 48 hrs.
|
22759318 |
| PBMC | IC50 |
0.10 μg/mL
|
Inhibition of T-lymphocyte proliferation in baboon peripheral blood mononuclear cells assessed by allogeneic mixed lymphocyte reaction with 3H-thymidine incorporation after 5 days.
Inhibition of T-lymphocyte proliferation in baboon peripheral blood mononuclear cells assessed by allogeneic mixed lymphocyte reaction with 3H-thymidine incorporation after 5 days.
|
25488654 |
| PBMC | IC50 |
0.15 μg/mL
|
Inhibition of T-lymphocyte proliferation in human peripheral blood mononuclear cells assessed by allogeneic mixed lymphocyte reaction with 3H-thymidine incorporation after 5 days.
Inhibition of T-lymphocyte proliferation in human peripheral blood mononuclear cells assessed by allogeneic mixed lymphocyte reaction with 3H-thymidine incorporation after 5 days.
|
25488654 |
In Vitro
FR104 (5 μg/mL; 30 min at room temperature) binds CD28 on human T lymphocytes with an ED50 of 0.32 μg/mL[1].
FR104 (0.001-10 μg/mL; 5 days) inhibits the proliferation of baboon and human T lymphocytes in a dose-dependent manner in allogeneic MLR, with an IC50 of 0.10 μg/mL for baboon PBMC and an IC50 of 0.15 μg/mL for human PBMC[2].
FR104 (1-10000 ng/mL; 5 days) inhibits baboon PBMC proliferation in an allogeneic mixed lymphocyte reaction[5].
FR104 (10 mg/mL; 8 days) reduces human tonsil pre-Tfh and Tfh cell proliferation more effectively than Belatacept (HY-108813)[5].
FR104 pretreatment does not impair the suppressive effect of NHP Tregs on Tconv allogeneic proliferation in MLR[3].
FR104 (10 µg/mL; 5 days) does not interfere with the suppressive function of natural CD4+CD25+ Treg cells from rhesus macaques in vitro, while inhibiting the proliferation of CD4+CD25− effector T cells[4].
FR104 (10 µg/mL; 5 days) blocks the ex vivo rhMOG-specific recall proliferative response of rhMOG-sensitized rhesus monkey monocytes, with an effect comparable to that of CTLA4-Ig[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:baboon and human T lymphocytes
-
Concentration:0.001, 0.01, 0.1, 1, 10 μg/mL
-
Incubation Time:5 days
-
Result:Dose-dependently inhibited the proliferation of baboon and human T lymphocytes in allogeneic MLR, with an IC50 of 0.10 μg/mL for baboon PBMC and an IC50 of 0.15 μg/mL for human PBMC.
-
Cell Line:CD4+CD25+ Treg cells from rhesus macaques and CD4+CD25− effector T cells
-
Concentration:10 µg/mL
-
Incubation Time:5 days
-
Result:Did not interfere with the suppressive function of natural CD4+CD25+ Treg cells from rhesus macaques in vitro, while inhibiting the proliferation of CD4+CD25− effector T cells.
Parmacokinetics
In Vivo
FR104 (5 mg/kg; intravenous injection; administered on days 0, 4, and 14, then once every 2 weeks until 3 months) in combination with Rapamycin (HY-10219) without steroids prevents acute renal allograft rejection during the 3-month dosing period[2].
FR104 (1-3.5 mg/kg; intravenous injection; single injection) achieves complete CD28 saturation in cynomolgus monkeys without inducing cytokine release[1].
FR104 (5 mg/kg; intravenous injection; administered on days 0, 4, and 14, then once every 2 weeks until 3 months) combined with MMF and steroids induces delayed rejection and prevents DSA production, but the effect is suboptimal, with half of the recipients developing rejection within 3 months[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/SCID (7 weeks old)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; single injection; one week after engraftment
-
Result:Did not induce human cytokine release compared with vehicle and reduced IFNγ release.
Did not elicit CD25 or CD69 activation markers on human T cells in blood or spleen.
-
Animal Model:NOD/SCID (7 weeks old)[1]
-
Dosage:5 mg/kg (monotherapy); 5 mg/kg (co-administered with 5 mg/kg anti-human CTLA-4 antibody)
-
Administration:i.p.; twice weekly; day 0 to day 25
-
Result:Prevented GVHD; mice showed no signs of disease, continued gaining weight, and survived through day 60.
No human T-cell infiltration was observed in liver, small intestine, or lung at 3 weeks after engraftment.
At 2 months after engraftment, mice had low human cell engraftment (< 10%).
Co-administration with a blocking anti-human CTLA-4 antibody completely abrogated protection against GVHD.
-
Animal Model:Cynomolgus monkeys (Macaca fascicularis)[1]
-
Dosage:1 mg/kg and 3.5 mg/kg
-
Administration:i.v.; single injection
-
Result:100% CD28 saturation was maintained as long as trough levels were above 0.5-2 µg/mL.
No cytokine release was observed after i.v. injection.
-
Animal Model:Cynomolgus monkeys (Macaca fascicularis)[2]
-
Dosage:5 mg/kg
-
Administration:i.v.; on days 0, 4, 14, then every 2 weeks until 3 months
-
Result:Mean survival time (MST) was 18.5 days; individual survival times were 14, 16, 21, and 28 days, all with acute rejection.
DSA development was prevented in all recipients.
At rejection, intragraft frequencies of Foxp3+, CTLA-4+, Foxp3+CTLA-4+, and Foxp3+Helios− T lymphocytes were significantly higher compared to controls.
Peripheral blood Tregs were > 90% Helios+ before transplantation; Helios-negative Tregs accumulated in frequency and number.
-
Animal Model:Renal allograft rejection model in baboons (Papio anubis, body weight 8-13 kg)[2]
-
Dosage:5 mg/kg (FR104); 35 mg/kg (MMF); 1 mg/kg/day (Solumedrol)
-
Administration:i.v.; on days 0, 4, 14, then every 2 weeks until 3 months; MMF p.o. twice daily from day 0 to day 90; Solumedrol i.v. daily from day 0 to day 14
-
Result:With MMF/steroids, an MST of 69.5 days was observed.
Survival times were 21, 49, 158, and 291 days; two recipients had acute rejection within 3 months (days 21 and 49), one had acute rejection after withdrawal at day 158, and one died of hypoglycemic coma at day 291.
DSA development was prevented in all recipients.
-
Animal Model:Renal allograft rejection model in baboons (Papio anubis, body weight 8-13 kg)[2]
-
Dosage:5 mg/kg (FR104); 0.05 mg/kg/day (tacrolimus)
-
Administration:i.v.; on days 0, 4, 14, then every 2 weeks until 3 months; tacrolimus i.m. daily from day 0 to day 90, adjusted to trough levels of 5-10 ng/mL
-
Result:With low-dose tacrolimus, allograft rejection was prevented over the 3-month dosing period.
Survival times were 77, 77, 84, and 112 days; three recipients were euthanized for ESBL-producing E. coli, Proteus mirabilis, and ESBL-producing E. coli, respectively; one had acute rejection after withdrawal at day 112.
No detectable DSA developed.
-
Animal Model:Renal allograft rejection model in baboons (Papio anubis, body weight 8–13 kg)[2]
-
Dosage:5 mg/kg (FR104); 1 mg/kg/day (rapamycin)
-
Administration:i.v.; on days 0, 4, 14, then every 2 weeks until 3 months; rapamycin p.o. daily from day 0 to day 90, adjusted to trough levels of 10-25 ng/mL
-
Result:With rapamycin, acute rejection was prevented over the 3-month dosing period.
Survival times were 84, 91, and 123 days; one unexplained death without rejection occurred at 84 days, one had an ESBL-producing E. coli infection at 91 days, and one had acute rejection after withdrawal at 123 days.
One recipient developed early IgG DSA without rejection.
-
Animal Model:baboons (Papio anubis, body weight 8–13 kg)[4]
-
Dosage:10 mg/kg (protein equivalent)
-
Administration:i.v.; days 0, 7, 14, and 21
-
Result:All six placebo-treated animals developed EAE and were euthanized on days 12, 13, 16, 18, 21, and 27.
None of the six animals developed EAE; they were euthanized on days 41, 41, 42, 42, 43, and 43 with EAE score 0.
Anti-rhMOG MNC proliferation in axillary lymph nodes was lower (stimulation index 2.42) than in placebo-treated animals (10.4); PBMC and spleen responses remained below the positive threshold (SI ≥ 3), except for monkey F3.
Serum anti-rhMOG IgM on day 11 was 126.1 AU and anti-rhMOG IgG was 14.02 AU; suppression of IgM and IgG production persisted throughout the observation period.
CSF anti-rhMOG IgM ranged from 0.000 to 20.90 AU, and anti-rhMOG IgG ranged from 0.000 to 2.100 AU.
No leukocytes were detected in the CSF.
Brain histology showed no inflammatory infiltrates in five of six animals; the remaining animal had only some small perivascular infiltrates.
Demyelination was observed in four of six placebo-treated animals; no demyelination was observed in the other six animals.
Brain mRNA for CD28, CTLA4, CD25, CCR7, IFN-γ, IL-6, CD63, and CXCL8 (IL-8) was lower relative to placebo; CD3 and CD19 mRNA levels were similar between groups.
CSF cytokine/chemokine medians included IL-2 0.00 pg/mL, IL-6 5.61 pg/mL, IL-12 0.00 pg/mL, IL-15 0.00 pg/mL, IFN-γ 0.00 pg/mL, IL-1RA 8.75 pg/mL, G-CSF 12.0 pg/mL, MIF 34.2 pg/mL, CCL2 123 pg/mL, CXCL10 2.79 pg/mL, CXCL11 3.36 pg/mL, IL-1β 0.56 pg/mL, IL-4 13.1 pg/mL, IL-5 5.12 pg/mL, IL-10 3.19 pg/mL, FGF-basic 0.00 pg/mL, GM-CSF 0.60 pg/mL, VEGF 0.00 pg/mL, and CXCL8 2.56 pg/mL.
At necropsy, serum IL-1β, CCL2, CCL11, and CCL22 were higher than in placebo-treated animals.
LCV DNA in blood increased after day 7, peaked at day 14, decreased at day 21, and increased again after day 21 in animals F1-F4; LCV was not detected in brain tissue.
Animal F3 had elevated CMV, LCV, and SA12 in tissues.
No marked reactivation was observed for CMV or the polyomaviruses; HEV was undetectable.
-
Animal Model:Papio anubis (8-13 kg)[5]
-
Dosage:10 mg/kg
-
Administration:i.v.; days 0, 7, and 14, then every 2 weeks; up to 1 year
-
Result:In recipients, two animals developed acute rejection on days 51 and 58; both reversed after steroid administration.
Two animals were lost to anesthetic complications or septicemia.
At 1 year, the three remaining animals had stable kidney function.
No animal had donor-specific antibodies by flow cytometry.
One-month protocol biopsies showed interstitial CD3+ T-cell infiltrate in all animals, with no differences in B-lymphocyte or major T-lymphocyte populations.
Blood CD25hi/CD127lo CD4+ Tregs and graft Foxp3 expression were not different; TSDR demethylation showed a trend toward a stronger Treg signal in animals, and TGFβ expression showed a nonsignificant increase.
No differences were found in CD28-negative CD4+ or CD8+ T cells, perforin, 2B4, PD1, or BTLA expression.
Th17-related transcripts (RORγc, IL-17, IL-23) were not different; graft IL-21 expression was lower than in belatacept group animals.
In rejection biopsies, CD4+PD1+ graft-infiltrating cells were 408/mm2 (n=2).
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Gene ID
Accession
Conjugated
Unconjugated
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized CD28 Protein, Human can bind FR104. The EC50 for this effect is 8.381 ng/mL. -
Flow cytometric analysis of 106 Jurkat cells with FR104 (HY-P990587, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor® 488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 kappa (HY-P99002, blue) was used as the isotype control.
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.08 kDa
-
Color Colorless to light yellow
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
Purity & Documentation
-
Data Sheet (287 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Poirier N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012 Oct;12(10):2630-40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)